Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

Simultaneous discoveries in art and science highlight humanity's shared creativity, problem-solving, and the ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

PRNewswire Bengaluru Karnataka [India] January 16 Bengaluru-based biotechnology startup CrisprBits Private Limited has ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

CRISPR Therapeutics is a mid-stage biotech ... Investor enthusiasm about technology and growth stocks, and the economic environment ahead, drove the momentum. After all, the artificial ...

In this installment, we delve into one of the most debated scientific advancements of our time: CRISPR gene-editing ...

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

It feels fantastic,” said Blau, who thanked her lab members and colleagues for their support and dedication. “This ...